Deciphering Immune Cell Heterogeneity and Transcriptomic Changes Associated with CRS Development and Severity in CAR-T Cell Treated Patients


The Mark Foundation for Cancer Research-Leukemia & Lymphoma Society Fellow (2021-Present)

Sylvain Simon, PhD, Fred Hutchinson Cancer Research Center

Dr. Simon has been awarded a grant focused on understanding the underlying biological mechanisms that cause many patients treated with CAR T-cell therapy to experience the dangerous, toxic immune response called cytokine release syndrome (CRS). The researchers will test pharmaceutical agents for CRS prevention and treatment.

Content courtesy of Leukemia & Lymphoma Society

BACK TO OUR PORTFOLIO